BNC KOREA, Inc (256840) Fair Value & Analysis
Healthcare · KR · Market cap 162B KRW
Fair value as of: Jul 22, 2026
From 15 valuation models · updated 19 days ago
Share price +9.8% over the past month.
Below-average quality, and screening another 50% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (1,488 KRW). The favourable scenario is already priced in.
- Weak quality (44/100) and above fair value at the same time, the margin of safety is missing on both counts.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.
How to read this chart
60‑month range 2,170 KRW – 55,414 KRW · fair‑value band 896.33 KRW – 1,488 KRW · the 2,750 KRW price screens above the 1,372 KRW fair value. Dashed = 300-day average. As of Jul 22, 2026.
Analysis
BNC KOREA, Inc (256840) currently trades at 2,750 KRW, while our model-based Fair Value estimate is 1,372 KRW, implying the stock looks roughly 50.1% overvalued today. The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, BNC KOREA, Inc generated revenue of 91.2B KRW at a net margin of -3.6%. Revenue declined 18.4% year over year. It earns a return on equity of -1.8%. Net debt stands at 20.4B KRW. Fundamentals as of Jul 22, 2026
Our scenario range runs from 896.33 KRW (bear case) to 1,488 KRW (bull case); at 2,750 KRW, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 55% below its 52-week high and 2% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -50%, 256840 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 15 models by family
Widest divergence: DCF Models (3,824 KRW) versus Multiples (912.42 KRW). Highest evidence: ROIC Compounder (72).
Notify me when 256840 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 48 · Market factors (momentum, volatility) 20
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
BNC KOREA, Inc. engages in the research and development, production, and sale of biomaterials for medicines in South Korea. The company offers BIENOX Inj.
Full company description
BNC KOREA, Inc. engages in the research and development, production, and sale of biomaterials for medicines in South Korea. The company offers BIENOX Inj. for temporary improvement of moderate to severe glabellar wrinkles associated with corrugator muscle and/or procerus muscle activity in adults; Juvegel for temporary improvement of moderate to severe nasolabial folds in adults; and Collapleo Plus, a collagen-based material for the supplementation of damaged or deficient ligaments, tendons, muscles, and fascia. It also provides HA fillers and skin booster fillers, including Cutegel, Cutegel Lidocaine, FLORE Lidocaine, Cutegel Hydro, S-DNA, and H-DNA, which are used to temporarily reduce facial wrinkles through physical restoration; Hibarry, a bio-absorbable gel and solution mixture used to prevent adhesion of the spinal cord post-surgery; and GentaQ a beauty face, and home and other care products under the I.st name. The company was formerly known as BNC Korea Co., Ltd. and changed its name to BNC KOREA, Inc. in April 2026. The company also exports its products to 45 countries. BNC KOREA, Inc. was incorporated in 2007 and is headquartered in Daegu, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
BNC KOREA, Inc reported revenue of 95.9B KRW in FY2025 versus 25.2B KRW in FY2021, a compound +39.6%/yr. Reported net income was 2.8B KRW in FY2025.
256840 screens 50% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →
Peer Group
Drug Manufacturers - Specialty & Generic · 621 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.19 | ¥25.94 | -51% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,933 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹7,316 | ₹1,943 | -73% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,763 | ₹1,329 | -72% |
| PharmaEssentia Corporation 6446 | 1,285 TWD | 221.01 TWD | -83% |
| Cipla Limited CIPLA | ₹1,439 | ₹1,001 | -30% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,151 | ₹703.32 | -39% |
| Lupin Limited LUPIN | ₹2,443 | ₹2,477 | +1% |
| Mankind Pharma Limited MANKIND | ₹2,484 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,211 | ₹874.79 | -28% |
Compare BNC KOREA, Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is BNC KOREA, Inc (256840) overvalued or undervalued?
What is the fair value of 256840?
What is the quality score of 256840?
What is the revenue of BNC KOREA, Inc (256840)?
What is the net profit margin of 256840?
Does BNC KOREA, Inc pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track BNC KOREA, Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.